

## **CURRICULUM VITAE**

Name: Celso Arango, MD, PhD  
Institution: Child and Adolescent Department of Psychiatry, Hospital General Universitario Gregorio Marañón  
Address: Ibiza, 43. 28009 Madrid. Spain  
Phone / Fax: +34- 914265006 / +34- 914265005  
e-mail: carango@hggm.es

## **EDUCATION**

1992 Degree in Medicine and Surgery. University of Oviedo, Spain.  
1986-1990 School of Medicine. University of Oviedo.  
1991-1992 School of Medicine. University of Manchester (UK), sponsored by the ERASMUS program.  
1997 Specialization in Psychiatry. Education and Culture Department. Hospital General Universitario Gregorio Marañón. Madrid, Spain.  
1997 Doctorate in Medicine (PhD). Complutense University of Madrid, Spain. Doctoral thesis: "Insight and violence in schizophrenia."

## **PROFESSIONAL EXPERIENCE**

1/93 to 12/96 Residency in Psychiatry. Hospital General Universitario Gregorio Marañón. Madrid. Spain.  
1/97 to 2/99 Research Fellow. Maryland Psychiatric Research Center. University of Maryland School of Medicine. Baltimore, MD, USA.  
6/99 to 2/09 Assistant Professor of Psychiatry. Department of Psychiatry. Hospital General Universitario Gregorio Marañón. Research Department. Complutense University, Madrid, Spain.  
2/09 to 12/17 Associate Professor of Psychiatry. Department of Psychiatry. Hospital General Universitario Gregorio Marañón. Research Department. Complutense University, Madrid, Spain.  
6/99 to 3/12 Head of Adolescent Psychiatric Unit. Department of Psychiatry. Hospital General Universitario Gregorio Marañón. Madrid, Spain.  
3/12 to present Head of Department. Department of Child and Adolescent Psychiatry. Hospital General Universitario Gregorio Marañón. Madrid, Spain.  
2/99 to 5/05 Volunteer Research Assistant Professor of Psychiatry. Maryland Psychiatric Research Center. University of Maryland School of Medicine. Baltimore, MD, USA.  
5/05 to 6/13 Volunteer Associate Professor of Psychiatry. Maryland Psychiatric Research Center. University of Maryland School of Medicine. Baltimore, MD, USA.  
1/08 to 12/16 Scientific Director. Spanish Mental Health Network (CIBERSAM). Ministry of Science, Innovation and Universities.  
6/13 to present Adjunct Professor of Psychiatry. Maryland Psychiatric Research Center. University of Maryland School of Medicine. Baltimore, MD, USA.  
7/15 to present Full Adjunct Professor of Psychiatry. Department of Psychiatry, University of California, San Francisco (UCSF), San Francisco, CA, USA.  
6/17 to present Visiting Professor. Department of Psychosis Studies within the Institute of Psychiatry, Psychology, & Neuroscience. King's College London, UK.  
1/18 to present Full Professor of Psychiatry. Department of Psychiatry. Hospital General Universitario Gregorio Marañón. Research Department. Complutense University, Madrid, Spain.

## **OVERVIEW:**

I am a scientist, clinician, and professor of psychiatry. My main area of interest is in the field of early-onset psychosis, especially early-onset schizophrenia. I have the largest cohort of first-episode early-onset psychosis patients followed for more than 15 years now. As a child psychiatrist, I have always been interested in translational research in early neurodevelopment (and have also published on autism and other neurodevelopmental disorders). I run the largest department of child and adolescent psychiatry in Spain. I published the first longitudinal studies comparing children and adolescents with different psychotic disorders (e.g., schizophrenia vs. bipolar disorders) showing that there are progressive brain disorders with loss of frontal gray matter in those who develop schizophrenia. I have also shown that this loss of gray matter is a marker of poor prognosis and is related to lower antioxidant levels (e.g., glutathione, GSH). I have also published extensively in the field of antipsychotics, mainly on their lack of effectiveness in negative symptoms and on their safety and tolerability in children and adolescents. I see patients two days a week in the first episode clinic at my university hospital and run a clinic for patients with 22q11 syndrome once a week. I am a professor of psychiatry in Madrid, as well as in the US (University of Maryland, UCSF) and the UK (KCL), and I am very active in educational organizations (e.g., president of the ECNP educational committee for the past 6 years).

I was the scientific director of the Spanish Center for Biomedical Research in Mental Health, (CIBERSAM, [www.cibersam.es](http://www.cibersam.es)) funded by the Spanish Ministry of Economy and Competitiveness, from its inception in 2008 until December 2016. The CIBERSAM is composed of 24 clinical and basic research groups belonging to 8 of the Autonomous Communities of Spain, which primarily perform research on mental disorders such as schizophrenia, depression, and bipolar disorder, as well as anxiety disorders, child and adolescent diseases, geriatric and neurodegenerative diseases and, in general, any neuroscientific aspect related to health and mental illness. The approach to studying these diseases has a clear translational component, seeking synergies among groups that perform their work in hospitals, research centers, and universities. The CIBERSAM comprises a human team of about 400 researchers, with a staff of more than 120 professionals hired by the Center, the rest being members of personnel groups attached to the CIBERSAM. I have been coordinator or PI for more than 10 European Commission-funded research projects (total funding of over 200 million euros) including the roadmap for mental health research for the European Commission. I have served on many executive committees for some of the most prestigious international societies and am currently president of the European College of Neuropsychopharmacology (ECNP).

My leadership experience in European psychiatry, along with my long-standing relationship with US psychiatry, may well be of interest to the American College of Psychiatry, blending European and American perspectives.

## **RESEARCH PROJECTS**

I have participated in more than 77 competitively funded research projects, as Principal Investigator in 55 of them. The research projects have been funded by the Spanish Ministry of Health, Spanish Ministry of Science, Innovation and Universities, NIMH, NARSAD, Stanley Foundation, Fundación Alicia Koplowitz, Caja Navarra, and the Department of Health in the State of Madrid, and I have participated in 10 EU projects funded by the VII Framework and H2020. I have been coordinator of the Spanish Network in Early Onset Psychosis and Mental Disease - Affective Disorders and Psychosis Research Network funded by the Ministry of Health.

## **SELECTED SCIENTIFIC PAPERS (I.F.: ISI 2017 Impact Factor)**

Arango, C.; Carpenter, W.T. Jr.; Queern, C.A. Research Ethics: A psychological approach. *Clinical Psychology Review*, 19(3): 384-5, 1999. (I.F.: 9.577).

Arango, C.; Adami, H.; Sherr, J.D.; Thacker, G.; Carpenter, W.T. Jr. Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness. *American Journal of Psychiatry*, 156(7): 1097-99, 1999. (I.F.: 13.391).

Carpenter, W.T. Jr.; Arango, C.; Buchanan, R.W.; Kirkpatrick, B. Deficit psychopathology and a paradigm shift in schizophrenia research. *Biological Psychiatry*, 46: 352-60, 1999. (I.F.: 11.982).

Arango, C.; Bartko, J.J.; Gold, J.M.; Buchanan, R.W. Prediction of neuropsychological performance by neurological signs in schizophrenia. *American Journal of Psychiatry*, 156(9): 1358-66, 1999. (I.F.: 13.391).

Arango, C.; Calcedo, A. Jr.; Gonzalez-Salvador, T.; Calcedo, A. Violence in inpatients with schizophrenia: a prospective study. *Schizophrenia Bulletin*, 25(3): 493-503, 1999. (I.F.: 6.944).

Arango, C.; Kirkpatrick, B.; Buchanan, R.W. Neurological signs and the heterogeneity of schizophrenia. *American Journal of Psychiatry*, 157(4): 560-5, 2000. (I.F.: 13.391).

Arango, C.; Kirkpatrick, B.; Koenig, J.I. At issue: stress, hippocampal neuronal turnover and neuropsychiatric disorders. *Schizophrenia Bulletin*, 27(3): 477-80, 2001. (I.F.: 6.944).

Arango, C.; Rojas, M.J.; Moreno, D.; Parellada, M. Sibutramine for compulsive eating in hypothalamic deficiency. *Journal of the American Academy of Child and Adolescent Psychiatry*, 41(10):1147-8, 2002. (I.F.: 6.250).

Arango, C.; Breier, A.; MacMahon, R.; Carpenter, W.T.; Buchanan, R.W. The relationship of clozapine and haloperidol treatment to prefrontal, hippocampal and caudate brain volumes. *American Journal of Psychiatry*, 160(8): 1421-7, 2003. (I.F.: 13.391).

Arango, C.; Summerfelt, A.; Buchanan, R.W. Olanzapine effects on auditory sensory gating in schizophrenia. *American Journal of Psychiatry*, 160(11): 2066-8, 2003. (I.F.: 13.391).

Buchanan, R.W.; Francis, A.; Arango, C.; Miller, K.; Lefkowitz, D.M.; McMahon, R.P.; Barta, P.E.; Pearlson, G.D. Morphometric assessment of the heteromodal cortex in schizophrenia. *American Journal of Psychiatry*, 161(2): 322-31, 2004. (I.F.: 13.391).

Bombín, I.; Arango, C.; Buchanan, R.W. Significance and meaning of neurological signs in schizophrenia: Two Decades Later. *Schizophrenia Bulletin*, 31(4): 962-77, 2005. (I.F.: 6.944).

Moreno, MD.; Burdalo M.; Reig, S.; Parellada, M.; Zabala, A.; Desco, M.; Baca-Baldomero, E.; Arango, C. Structural neuroimaging in adolescents with a first psychotic episode. *Journal of the American Academy of Child and Adolescent Psychiatry*, 44(11): 1151-1157, 2005. (I.F.: 6.250).

Artaloytia, J.F.; Arango, C.; Lahti, A.; Sanz, J.; Pascual, A.; Cubero, P.; Prieto, D.; Palomo, T. Negative signs and symptoms secondary to antipsychotics: A double-blind randomized trial of single dose of placebo, haloperidol and risperidone in healthy volunteers. *American Journal of Psychiatry*, 163(3): 488-93, 2006. (I.F.: 13.391).

Soto-Montenegro, M.L.; Vaquero, J.J.; Arango, C.; Ricaurte, G.; Garcia-Barreno, P.; Desco, M. Effects of MDMA administration on blood glucose levels and brain glucose metabolism. *European Journal of Nuclear Medicine and Molecular Imaging*, 34(6):916-25, 2007. (I.F.: 7.704).

Robles, O.; Blaxton, T.; Adami, H.; Arango, C.; Thaker, G.; Gold, J. Nonverbal delayed recognition in the relatives of schizophrenia patients with or without schizophrenia spectrum. *Biological Psychiatry*, 63(5):498-504, 2008. (I.F.: 11.982).

Arango, C.; Moreno, C.; Martínez, S.; Parellada, M.; Desco, M.; Moreno, D.; Fraguas, D.; Gogtay, N.; James, A.; Rapoport, J. Longitudinal Brain Changes in Early-Onset Psychosis. *Schizophrenia Bulletin*, 34(2):341-53, 2008. (I.F.: 6.944).

- Arango, C.; Kahn, R. Progressive Brain Changes in Schizophrenia. *Schizophrenia Bulletin*, 34(2):310-1, 2008. (I.F.: 6.944).
- Rosa, AR.; Franco, C.; Martínez-Aran, A.; Sánchez-Moreno, J.; Reinares, M.; Salamero, M.; Arango, C.; Ayuso-Mateos, JL.; Kapczinski, F.; Vieta, E. Functional impairment in patients with remitted bipolar disorder. *Psychotherapy and Psychosomatics*, 77(6):390-392, 2008. (I.F.: 13.122).
- Janssen, J.; Reig, S.; Parellada, M.; Moreno, MD.; Graell, M.; Fraguas, D.; Zabala, A.; García-Vazquez, V.; Desco, M.; Arango, C. Regional gray matter volume deficits in adolescents with first-episode psychosis. *Journal of the American Academy of Child and Adolescent Psychiatry*, 47(11):1311-20, 2008. (I.F.: 6.250).
- Parellada, M.; Fraguas, D.; Bombín, I.; Otero, S.; Castro-Fornieles, J.; Baeza, I.; Gonzalez-Pinto, A.; Graell, M.; Soutullo, C.; Payá, B.; Arango, C. Insight correlates in child- and adolescent-onset first episodes of psychosis: results from the CAFEPS study. *Psychological Medicine*, 39(9):1433-45, 2009. (I.F.: 5.475).
- Reig, S.; Moreno, C.; Moreno, D.; Burdalo, M.; Janssen, J.; Parellada, M.; Zabala, A.; Desco, M.; Arango, C. Progression of brain volume changes in adolescent-onset psychosis. *Schizophrenia Bulletin*, 35(1):233-43, 2009. (I.F.: 6.944).
- Balanzá-Martínez, V.; Cuesta, MJ.; Arango, C.; Crespo-Facorro, B.; Tabarés-Seisdedos, R. Longitudinal course of cognition in schizophrenia. *British Journal of Psychiatry*, 195(1):84, 2009. (I.F.: 5.867).
- Stefansson, H.; Ophoff, RA.; Steinberg, S.; Andreassen, OA.; Cichon, S.; Rujescu, D.; Werge, T.; Pietiläinen, OP.; Mors, O.; Mortensen, PB.; Sigurdsson, E.; Gustafsson, O.; Nyegaard, M.; Tuulio-Henriksson, A.; Ingason, A.; Hansen, T.; Suvisaari, J.; Lonnqvist, J.; Paunio, T.; Børglum, AD.; Hartmann, A.; Fink-Jensen, A.; Nordentoft, M.; Hougaard, D.; Norgaard-Pedersen, B.; Böttcher, Y.; Olesen, J.; Breuer, R.; Möller, HJ.; Giegling, I.; Rasmussen, HB.; Timm, S.; Mattheisen, M.; Bitter, I.; Réthelyi, JM.; Magnusdottir, BB.; Sigmundsson, T.; Olason, P.; Masson, G.; Gulcher, JR.; Haraldsson, M.; Fossdal, R.; Thorgeirsson, TE.; Thorsteinsdottir, U.; Ruggieri, M.; Tosato, S.; Franke, B.; Strengman, E.; Kiemenev, LA.; Genetic Risk and Outcome in Psychosis (GROUP); Melle, I.; Djurovic, S.; Abramova, L.; Kaleda, V.; Sanjuan, J.; de Frutos, R.; Bramon, E.; Vassos, E.; Fraser, G.; Ettinger, U.; Picchioni, M.; Walker, N.; Touloupoulou, T.; Need, AC.; Ge, D.; Yoon, JL.; Shianna, KV.; Freimer, NB.; Cantor, RM.; Murray, R.; Kong, A.; Golimbet, V.; Carracedo, A.; Arango, C.; Costas, J.; Jönsson, EG.; Terenius, L.; Agartz, I.; Petursson, H.; Nöthen, MM.; Rietschel, M.; Matthews, PM.; Muglia, P.; Peltonen, L.; St Clair, D.; Goldstein, DB.; Stefansson, K.; Collier, DA. Common variants conferring risk of schizophrenia. *Nature*, 460(7256):744-7, 2009. (I.F.: 41.577).
- Janssen, J.; Diaz-Caneja, A.; Reig, S.; Bombín, I.; Mayoral, M.; Parellada, M.; Graell, M.; Moreno, D.; Zabala, A.; Garcia-Vazquez, V.; Desco, M.; Arango, C. Brain morphology and neurological soft signs in adolescents with first-episode psychosis. *British Journal of Psychiatry*, 195(3):227-33, 2009. (I.F.: 5.867).
- Janssen, J.; Reig, S.; Aleman, Y.; Schnack, H.; Udias, JM.; Parellada, M.; Graell, M.; Moreno, D.; Zabala, A.; Balaban, E.; Desco, M.; Arango, C. Gyral and sulcal cortical thinning in adolescents with first episode early-onset psychosis. *Biological Psychiatry*, 66(11):1047-54, 2009. (I.F.: 11.982).
- Arango, C.; Amador, X. Lessons learned about poor insight. *Schizophrenia Bulletin*, 37(1):27-8, 2011. (I.F.: 6.944).
- Parellada, M.; Boada, L.; Fraguas, D.; Reig, S.; Castro-Fornieles, J.; Moreno, D.; Gonzalez-Pinto, A.; Otero, S.; Rapado-Castro, M.; Graell, M.; Baeza, I.; Arango, C. Trait and state attributes of insight in first Episodes of early-onset schizophrenia and other psychoses: A 2-year longitudinal study. *Schizophrenia Bulletin*, 37(1):38-51, 2011. (I.F.: 6.944).
- Ayuso-Mateos, JL.; Wykes, T.; Arango, C. The Madrid Declaration: why we need a coordinated European-wide effort in mental health research. *British Journal of Psychiatry*, 198:253-5, 2011. (I.F.: 5.867).
- Robles, O.; Zabala, A.; Bombín, I.; Parellada, M.; Moreno, D.; Ruiz-Sancho, A.; Arango, C. Cognitive Efficacy of Quetiapine and Olanzapine in Early-Onset First-Episode Psychosis. *Schizophrenia Bulletin*, 37(2):405-15, 2011. (I.F.: 6.944).
- González-Pinto, A.; Alberich, S.; Barbeito, S.; Gutierrez, M.; Vega, P.; Ibáñez, B.; Haidar, MK.; Vieta, E.; Arango, C. Cannabis and first-episode psychosis: Different long-term outcomes depending on continued or discontinued use. *Schizophrenia Bulletin*, 37(3):631-9, 2011. (I.F.: 6.944).

- Descio, M.; Navas-Sanchez, FJ.; Sanchez-González, J.; Reig, S.; Robles, O.; Franco, C.; Guzmán-De-Villoria, J.; García-Barreno, P.; Arango, C. Mathematically gifted adolescents use more extensive and more bilateral areas of the fronto-parietal network than controls during executive functioning and fluid reasoning tasks. *Neuroimage*, 57(1): 281–92, 2011. (I.F.: 5.426).
- Castro-Fornieles, J.; Baeza, I.; de la Serna, E.; Gonzalez-Pinto, A.; Parellada, M.; Graell, M.; Moreno, D.; Otero, S.; Arango, C. Two-year diagnostic stability in early-onset first-episode psychosis. *Journal of Child Psychology and Psychiatry*, 52(10):1089-98, 2011. (I.F.: 6.486).
- Cuerda, C.; Merchan-Naranjo, J.; Velasco, C.; Gutierrez, A.; Leiva, M.; de Castro MJ.; Parellada, M.; Giráldez, M.; Bretón, I.; Cambor, M.; García-Peris, P.; Dulín, E.; Sanz, I.; Descio, M.; Arango, C. Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics. *Clinical Nutrition*, 30(5):616-23, 2011. (I.F.: 5.496).
- Reig, S.; Parellada, M.; Castro-Fornieles, J.; Janssen, J.; Moreno, D.; Baeza, I.; Bargalló, N.; González-Pinto, A.; Graell, M.; Ortuño, F.; Otero, S.; Arango, C.; Descio, M. Multicenter study of brain volume abnormalities in children and adolescent-onset psychosis. *Schizophrenia Bulletin*, 37(6):1270-80, 2011. (I.F.: 6.944).
- Arango, C.; Rapado Castro, M.; Reig, S.; Castro-Fornieles, J.; González-Pinto, A.; Otero Cuesta, S.; Baeza, I.; Moreno, C.; Graell, M.; Janssen, J.; Parellada, M.; Moreno, D.; Bargalló, N.; Descio, M. Progressive brain changes in children and adolescents with first-episode psychosis. *JAMA Psychiatry*, 69(1):16-26, 2012. (I.F.: 16.642).
- Janssen, J.; Aleman, Y.; Reig, S.; Schnack, H.; Parellada, M.; Graell, M.; Moreno, C.; Moreno, MD.; Mateos-Pérez, JM.; Udias, JM.; Arango, C.; Descio, M. Regional specificity of thalamic volume deficits in male adolescents with early-onset psychosis. *British Journal of Psychiatry*, 200: 30-6, 2012. (I.F.: 5.867).
- Mayoral, M.; Bombín, I.; Castro-Fornieles, J.; González-Pinto, A.; Otero, S.; Parellada, M.; Moreno, D.; Baeza, I.; Graell, M.; Rapado, M.; Arango, C. Longitudinal study of neurological soft signs in first-episode early-onset psychosis. *Journal of Child Psychology and Psychiatry*, 53(3):323-31, 2012. (I.F.: 6.486).
- Nuevo, R.; Chatterji, S.; Verdes, E.; Naidoo, N.; Arango, C.; Ayuso-Mateos, JL. The Continuum of Psychotic Symptoms in the General Population: A Cross-national Study. *Schizophrenia Bulletin*, 38(3):475-85, 2012. (I.F.: 6.944).
- Bombin, I.; Mayoral, M.; Castro-Fornieles, J.; Gonzalez-Pinto, A.; de la Serna, E.; Rapado-Castro, M.; Barbeito, S.; Parellada, M.; Baeza, I.; Graell, M.; Payá, B.; Arango, C. Neuropsychological evidence for abnormal neurodevelopment associated with early onset psychoses. *Psychological Medicine*, 43(4):757-68, 2013. (I.F.: 5.475).
- Arango, C. Child neuropsychopharmacology: good news... the glass is half full. *World Psychiatry*, 12(2):128-9, 2013. (I.F.: 30.000).
- Torrent, C.; del Mar Bonnin, C.; Martinez-Arán, A.; del Valle, J.; Amann, B.; González-Pinto, A.; Crespo, JM; Ibañez, A.; Garcia-Portilla, MP; Tabarés-Seisdedos, R.; Arango, C.; Colom, F.; Solé B.; Pacchiarotti, I.; Rosa, AR.; Ayuso-Mateos, JL; Anaya, C; Fernández, P.; Landín-Romero, R; Alonso, S.; Ortiz-Gil, A.; Segura, B.; Barbeito, S.; Vega, S.; Fernández, S.; Ugarte, A.; Subirà, A; Cerrillo, E.; Custal, N.; Menchón, JM.; Saiz-Ruiz, J.; Rodao, MJ.; Isella, S.; Alegría, A.; Al-Halabi, S.; Bobes, J.; Galván, G.; Saiz, PA.; Balanzá-Martínez, V.; Selva, G.; Fuentes-Durá, I.; Correa, P.; Mayoral, M.; Chiclana, G.; Merchan-Naranjo, J.; Rapado-Castro, M.; Salamero, M.; Vieta, E. Efficacy of Functional Remediation in Bipolar Disorder: A Multicentre, Randomized-Controlled Study. *American Journal of Psychiatry*, 170(8):852-9, 2013. (I.F.: 13.391).
- Moreno, C.; Nuevo, R.; Chatterji, S.; Verdes, E.; Arango, C.; Ayuso-Mateos, JL. Psychotic symptoms are associated with physical health problems independently of a mental disorder diagnosis: results from the WHO World Health Survey. *World Psychiatry*, 12(3):251-257, 2013. (I.F.: 30.000).
- Alemán-Gómez, Y.; Janssen, J.; Schnack, H.; Balaban, E.; Pina-Camacho, L.; Alfaro-Almagro, F.; Castro-Fornieles, J.; Otero, S.; Baeza, I.; Moreno, D.; Bargalló, N.; Parellada, M.; Arango, C.; Descio, M. The Human Cerebral Cortex Flattens during Adolescence. *Journal of Neuroscience*, 33(38):15004-15010, 2013. (I.F.: 5.970).
- Steinberg, S.; de Jong, S.; Mattheisen, M.; Costas, J.; Demontis, D.; Jamain, S.; Pietiläinen, OP.; Lin, K.; Papiol, S.; Huttenlocher, J.; Sigurdsson, E.; Vassos, E.; Giegling, I.; Breuer, R.; Fraser, G.; Walker, N.; Melle, I.; Djurovic, S.; Agartz, I.; Tuulio-Henriksson, A.; Suvisaari, J.; Lönqvist, J.; Paunio, T.; Olsen, L.; Hansen, T.; Ingason, A.; Pirinen, M.;

Strengman, E.; Hougaard, DM.; Orntoft, T.; Didriksen, M.; Hollegaard, MV.; Nordentoft, M.; Abramova, L.; Kaleda, V.; Arrojo, M.; Sanjuán, J.; Arango, C.; Etain, B.; Bellivier, F.; Méary, A.; Schürhoff, F.; Szoke, A.; Ribolsi, M.; Magni, V.; Siracusano, A.; Sperling, S.; Rossner, M.; Christiansen, C.; Kiemeny, LA.; Franke, B.; van den Berg, LH.; Veldink, J.; Curran, S.; Bolton, P.; Poot, M.; Staal, W.; Rehnstrom, K.; Kilpinen, H.; Freitag, CM.; Meyer, J.; Magnusson, P.; Saemundsen, E.; Martsenkovsky, I.; Bikshaieva, I.; Martsenkovska, I.; Vashchenko, O.; Raleva, M.; Paketchieva, K.; Stefanovski, B.; Durmishi, N.; Pejovic Milovancevic, M.; Lecic Tosevski, D.; Silagadze, T.; Naneishvili, N.; Mikeladze, N.; Surguladze, S.; Vincent, JB.; Farmer, A.; Mitchell, PB.; Wright, A.; Schofield, PR.; Fullerton, JM.; Montgomery, GW.; Martin, NG.; Rubino, IA.; van Winkel, R.; Kenis, G.; De Hert, M.; Réthelyi, JM.; Bitter, I.; Terenius, L.; Jönsson, EG.; Bakker, S.; van Os, J.; Jablensky, A.; Leboyer, M.; Bramon, E.; Powell, J.; Murray, R.; Corvin, A.; Gill, M.; Morris, D.; O'Neill, FA.; Kendler, K.; Riley, B.; Wellcome Trust Case Control Consortium 2.; Craddock, N.; Owen, MJ.; O'Donovan, MC.; Thorsteinsdottir, U.; Kong, A.; Ehrenreich, H.; Carracedo, A.; Golimbet, V.; Andreassen, OA.; Børglum, AD.; Mors, O.; Mortensen, PB.; Werge, T.; Ophoff, RA.; Nöthen, MM.; Rietschel, M.; Cichon, S.; Ruggeri, M.; Tosato, S.; Palotie, A.; St Clair, D.; Rujescu, D.; Collier, DA.; Stefansson, H.; Stefansson K. Common variant at 16p11.2 conferring risk of psychosis. *Molecular Psychiatry*, 19(1):108-14, 2014. (I.F.: 11.640).

Arango, C.; Fraguas, D.; Parellada, M. Differential neurodevelopmental trajectories in patients with early-onset bipolar and schizophrenia disorders. *Schizophrenia Bulletin*, 40(Suppl 2):S138-46, 2014. (I.F.: 6.944).

Fleischhacker, W.; Arango, C.; Arteel, P.; Barnes, T.; Carpenter, W.; Duckworth, K.; Galderisi, S.; Halpern, L.; Knapp, M.; Marder, SR.; Moller, M.; Sartorius, N.; Woodruff, P. Schizophrenia--time to commit to policy change. *Schizophrenia Bulletin*, 40(Suppl 3): S165-94, 2014. (I.F.: 6.944).

Calvo, A.; Moreno, M.; Ruiz, A.; Rapado-Castro, M.; Moreno, C.; Sánchez-Gutiérrez, S.; Arango, C.; Mayoral, M. Intervention for adolescents with early onset psychosis and their families: a randomized controlled trial. The PIENSA program. *Journal of the American Academy of Child and Adolescent Psychiatry*, 53(6):688-96, 2014. (I.F.: 6.250).

European Network of National Networks studying Gene-Environment Interactions in Schizophrenia (EU-GEI). Identifying gene-environment interactions in schizophrenia: Contemporary challenges for integrated, large-scale investigations. *Schizophrenia Bulletin*, 40(4):729-36, 2014. (I.F.: 6.944).

Díaz-Caneja, CM.; Moreno, C.; Llorente, C.; Espliego, A.; Arango, C.; Moreno, D. Practitioner Review: Long-term pharmacological treatment of pediatric bipolar disorder. *Journal of Child Psychology and Psychiatry*, 55(9):959-80, 2014. (I.F.: 6.486).

O'Donnell, P.; Do, KQ.; Arango, C. Oxidative/Nitrosative Stress in Psychiatric Disorders: Are We There Yet?. *Schizophrenia Bulletin*, 40(5):960-2, 2014. (I.F.: 6.944).

Arango, C.; Giráldez, M.; Merchán-Naranjo, J.; Baeza, I.; Castro-Fornieles, J.; Alda, JA.; Martínez-Cantarero, C.; Moreno, C.; de Andrés, P.; Cuerda, C.; de la Serna, E.; Correll, C.; Fraguas, D.; Parellada, M. Second-Generation Antipsychotic Use in Children and Adolescents: A Six-Month Prospective Cohort Study in Drug-Naïve Patients. *Journal of the American Academy of Child and Adolescent Psychiatry*, 53(11):1179-1190, 2014. (I.F.: 6.250).

Arango, C. The other side of bipolar disorder. *American Journal of Psychiatry*, 171(11):1145-7, 2014. (I.F.: 13.391).

Arango, C.; Kahn, RS. More Treatment for Those Most in Need? A Foregone Conclusion?. *Schizophrenia Bulletin*, 41(1):26-7, 2015. (I.F.: 6.944).

Dazzan, P.; Arango, C.; Fleischacker, W.; Galderisi, S.; Glenthøj, B.; Leucht, S.; Meyer-Lindenberg, A.; Kahn, R.; Rujescu, D.; Sommer, I.; Winter, I.; McGuire, P. Magnetic Resonance Imaging and the Prediction of Outcome in First-Episode Schizophrenia: A Review of Current Evidence and Directions for Future Research. *Schizophrenia Bulletin*, 41(3):574-83, 2015. (I.F.: 6.944).

Leucht, S.; Winter-van Rossum, I.; Heres, S.; Arango, C.; Fleischacker, WW.; Glenthøj, B.; Leboyer, M.; Leweke, FM.; Lewis, S.; McGuire, P.; Meyer-Lindenberg, A.; Rujescu, D.; Kapur, S.; Kahn, RS.; Sommer, IE. The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for its Methodology and a Review of the Effectiveness of Switching Antipsychotics. *Schizophrenia Bulletin*, 41(3):549-58, 2015. (I.F.: 6.944).

Drake, RJ.; Nordentoft, M.; Haddock, G.; Arango, C.; Fleischacker, WW.; Glenthøj, B.; Leboyer, M.; Leucht, S.; Leweke, M.; McGuire, P.; Meyer-Lindenberg, A.; Rujescu, D.; Sommer, IE.; Kahn, RS.; Lewis, SW. Modeling

- Determinants of Medication Attitudes and Poor Adherence in Early Nonaffective Psychosis: Implications for Intervention. *Schizophrenia Bulletin*, 41(3):584-96, 2015. (I.F.: 6.944).
- Arango, C.; Kapur, S.; Kahn, RS. Going Beyond "trial-and-error" in Psychiatric Treatments: OPTiMiSE-ing the Treatment of First Episode of Schizophrenia. *Schizophrenia Bulletin*, 41(3):546-8, 2015. (I.F.: 6.944).
- Fond, G.; d'Albis, MA.; Jamain, S.; Tamouza, R.; Arango, C.; Fleischhacker, WW.; Glenthøj, B.; Leweke, M.; Lewis, S.; McGuire, P.; Meyer-Lindenberg, A.; Sommer, IE.; Winter-van, Rossum, I.; Kapur, S.; Kahn, RS.; Rujescu, D.; Leboyer, M. The Promise of Biological Markers for Treatment Response in First-Episode Psychosis: A Systematic Review. *Schizophrenia Bulletin*, 41(3):559-73, 2015. (I.F.: 6.944).
- Vorstman, JA.; Breetvelt, EJ.; Duijff, SN.; Eliez, S.; Schneider, M.; Jalbrzikowski, M.; Armando, M.; Vicari, S.; Shashi, V.; Hooper, SR.; Chow, EW.; Fung, WL.; Butcher, NJ.; Young, DA.; McDonald-McGinn, DM.; Vogels, A.; van, Amelsvoort, T.; Gothelf, D.; Weinberger, R.; Weizman, A.; Klaassen, PW.; Kooops, S.; Kates, WR.; Antshel, KM.; Simon, TJ.; Ousley, OY.; Swillen, A.; Gur, RE.; Bearden, CE.; Kahn, RS.; Bassett, AS.; for the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Cognitive Decline Preceding the Onset of Psychosis in Patients with 22q11.2 Deletion Syndrome. *JAMA Psychiatry*, 72(4):377-85, 2015. (I.F.: 16.642).
- Sanchez-Gistau, V.; Baeza, I.; Arango, C.; González-Pinto, A.; de la Serna, E.; Parellada, M.; Graell, M.; Paya, B.; Llorente, C.; Castro-Fornieles, J. The affective dimension of early-onset psychosis and its relationship with suicide. *Journal of Child Psychology and Psychiatry*, 56(7):747-55, 2015. (I.F.: 6.486).
- Leza, JC.; Bueno, B.; Bioque, M.; Arango, C.; Parellada, M.; Do, K.; O'Donnell, P.; Bernardo M. Inflammation in schizophrenia: A question of balance. *Neuroscience and Biobehavioral Reviews*, 55:612-626, 2015. (I.F.: 8.037).
- Bos, DJ.; Merchán-Naranjo, J.; Martínez, K.; Pina-Camacho, L.; Balsa, I.; Boada, L.; Schnack, H.; Oranje, B.; Desco, M.; Arango, C.; Parellada, M.; Durston, S.; Janssen, J. Reduced Gyrfication Is Related to Reduced Interhemispheric Connectivity in Autism Spectrum Disorders. *Journal of the American Academy of Child and Adolescent Psychiatry*, 54(8):668-76, 2015. (I.F.: 6.250).
- Arango, C. First-Episode Psychosis Research: Time to Move Forward (by Looking Backwards). *Schizophrenia Bulletin*, 41(6):1205-6, 2015. (I.F.: 6.944).
- Calvo, A.; Moreno, M.; Ruiz-Sancho, A.; Rapado-Castro, M.; Moreno, C.; Sánchez-Gutiérrez, T.; Arango, C.; Mayoral, M. Psychoeducational group intervention for adolescents with psychosis and their families: a two-year follow-up. *Journal of the American Academy of Child and Adolescent Psychiatry*, 54(12):984-90, 2015. (I.F.: 6.250).
- Wykes, T.; Haro, JM.; Belli, SR.; Obradors-Tarragó, C.; Arango, C.; Ayuso-Mateos, JL.; Bitter, I.; Brunn, M.; Chevreur, K.; Demotes-Mainard, J.; Elfeddali, I.; Evans-Lacko, S.; Fiorillo, A.; Forsman, AK.; Hazo, JB.; Kuepper, R.; Knappe, S.; Leboyer, M.; Lewis, SW.; Linszen, D.; Luciano, M.; Maj, M.; McDaid, D.; Miret, M.; Papp, S.; Park, AL.; Schumann, G.; Thornicroft, G.; van der Feltz-Cornelis, C.; van Os, J.; Wahlbeck, K.; Walker-Tilley, T.; Wittchen, HU; ROAMER consortium. Mental health research priorities for Europe. *Lancet Psychiatry*, 2(11):1036-42, 2015. (I.F.: 15.233).
- Bonnin, CM.; Torrent, C.; Arango, C.; Amann, BL.; Solé, B.; González-Pinto, A.; Crespo, JM.; Tabarés-Seisdedos, R.; Reinares, M.; Ayuso-Mateos, JL.; García-Portilla, MP.; Ibañez, Á.; Salamero, M.; Vieta, E.; Martínez-Aran, A.; CIBERSAM Functional Remediation Group. Functional remediation in bipolar disorder: 1-year follow-up of neurocognitive and functional outcome. *British Journal of Psychiatry*, 208(1):87-93, 2016. (I.F.: 5.867).
- Bonnin, CM.; Reinares, M.; Martínez-Arán, A.; Balanzá-Martínez, V.; Solé, B.; Torrent, C.; Tabarés-Seisdedos, R.; García-Portilla, MP.; Ibañez, A.; Amann, BL.; Arango, C.; Ayuso-Mateos, JL.; Crespo, JM.; González-Pinto, A.; Colom, F.; Vieta, E.; CIBERSAM Functional Remediation Group. Effects of functional remediation on neurocognitively impaired bipolar patients: enhancement of verbal memory. *Psychological Medicine*, 46(2):291-301, 2016. (I.F.: 5.475).
- Arango, C.; Fraguas, D. Should psychiatry deal only with mental disorders without an identified medical aetiology?. *World Psychiatry*, 15(1):22-3, 2016. (I.F.: 30.000).
- Pina-Camacho, L.; Rey-Mejías, A. Del; Janssen, J.; Bioque, M.; González-Pinto, A.; Arango, C.; Lobo, A.; Sarró, A.; Desco, M.; Sanjuan, J.; Lacalle-Aurioles, M.; Cuesta, MJ.; Saiz-Ruiz, J.; Bernardo, M.; Parellada, M.; PEPs Group. Age at first episode modulates diagnosis-related structural brain abnormalities in psychosis. *Schizophrenia Bulletin*, 42(2):344-57, 2016. (I.F.: 6.944).

Galling, B.; Roldán, A.; Nielsen, RE.; Nielsen, J.; Gerhard, T.; Carbon, M.; Stubbs, B.; Vancampfort, D.; De Hert, M.; Olfson, M.; Kahl, KG.; Martin, A.; Guo, JJ.; Lane, HY.; Sung, FC.; Liao, CH.; Arango, C.; Correll, CU. Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. *JAMA Psychiatry*, 73(3):247-59, 2016. (I.F.: 16.642).

Fraguas, D.; Díaz-Caneja, CM.; State, MW.; O'Donovan, MC.; Gur, RE.; Arango, C. Mental disorders of known aetiology and precision medicine in psychiatry: a promising but neglected alliance. *Psychological Medicine*, 47(2):193-197, 2017. (I.F.: 5.475).

Montejo, ÁL.; Arango, C.; Bernardo, M.; Carrasco, JL.; Crespo-Facorro, B.; Cruz, JJ.; Del Pino-Montes, J.; García-Escudero, MA.; García-Rizo, C.; González-Pinto, A.; Hernández, AI.; Martín-Carrasco, M.; Mayoral-Cleries, F.; Mayoral-van Son, J.; Mories, MT.; Pachiarotti, I.; Pérez, J.; Ros, S.; Vieta, E. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. *Frontiers in Neuroendocrinology*, 45:25-34, 2017. (I.F.: 6.875).

Martínez, K.; Janssen, J.; Ángel Pineda-Pardo, J.; Carmona, S.; Javier Román, F.; Alemán-Gómez, Y.; Garcia-Garcia, D.; Escorial, S.; Ángeles Quiroga, M.; Santarnecchi, E.; Javier Navas-Sánchez, F.; Desco, M.; Arango, C.; Colom, R. Individual differences in the dominance of interhemispheric connections predict cognitive ability beyond sex and brain size. *Neuroimage*, 155:234-244, 2017. (I.F.: 5.426).

Bugarski-Kirola, D.; Blaettler, T.; Arango, C.; Fleischhacker, WW.; Garibaldi, G.; Wang, A.; Dixon, M.; Bressan, RA.; Nasrallah, H.; Lawrie, S.; Napieralski, J.; Ochi-Lohmann, T.; Reid, C.; Marder, SR. Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies. *Biological Psychiatry*, 82(1):8-16, 2017. (I.F.: 11.982).

Lim, ET.; Uddin, M.; De Rubeis, S.; Chan, Y.; Kamumbu, AS.; Zhang, X.; D'Gama, AM.; Kim, SN.; Hill, RS.; Goldberg, AP.; Poultney, C.; Minshew, NJ.; Kushima, I.; Aleksic, B.; Ozaki, N.; Parellada, M.; Arango, C.; Penzol, MJ.; Carracedo, A.; Kolevzon, A.; Hultman, CM.; Weiss, LA.; Fromer, M.; Chiacchetti, AG.; Freitag, CM; Autism Sequencing Consortium.; Church, GM.; Scherer, SW.; Buxbaum, JD.; Walsh, CA. Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder. *Nature Neuroscience*, 20(9):1217-1224, 2017. (I.F.:19.912).

Parellada, M.; Pina-Camacho, L.; Moreno, C.; Aleman, Y.; Krebs, MO.; Desco, M.; Merchán-Naranjo, J.; Del Rey-Mejías, A.; Boada, L.; Llorente, C.; Moreno, D.; Arango, C.; Janssen, J. Insular pathology in young people with high-functioning autism and first-episode psychosis. *Psychological Medicine*, 47(14):2472-2482, 2017. (I.F.: 5.475).

Parellada, M.; Gomez-Vallejo, S.; Burdeus, M.; Arango, C. Developmental Differences between Schizophrenia and Bipolar Disorder. *Schizophrenia Bulletin*, 43(6):1176-89, 2017. (I.F.: 6.944).

Sommer, IE.; Arango, C. Moving interventions from after to before diagnosis. *World Psychiatry*, 16(3):275-276, 2017. (I.F.: 30.000).

Gur, RE.; Bassett, AS.; McDonald-McGinn, DM.; Bearden, CE.; Chow, E.; Emanuel, BS.; Owen, M.; Swillen, A.; Van den Bree, M.; Vermeesch, J.; Vorstman, JAS.; Warren, S.; Lehner, T.; Morrow, B.; and The International 22q11.2 Deletion Syndrome Brain Behavior Consortium. A neurogenetic model for the study of schizophrenia spectrum disorders: The International 22q11.2 Deletion Syndrome Brain Behavior Consortium. *Molecular Psychiatry*, 22(12):1664-1672, 2017. (I.F.: 11.640).

Jongsma, HE.; Gayer-Anderson, C.; Lasalvia, A.; Quattrone, D.; Mulè, A.; Szöke, A.; Selten, JP.; Turner, C.; Arango, C.; Tarricone, I.; Berardi, D.; Tortelli, A.; Llorca, PM.; de Haan, L.; Bobes, J.; Bernardo, M.; Sanjuán, J.; Santos, JL.; Arrojo, M.; Del-Ben, CM.; Menezes, PR.; Murray, RM.; Rutten, BP.; Jones, PB.; van Os, J.; Morgan, C.; Kirkbride, JB; European Network of National Schizophrenia Networks Studying Gene-Environment Interactions Work Package 2 (EU-GEI WP2) Group. Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study. *JAMA Psychiatry*, 75(1):36-46, 2018. (I.F.: 16.642).

van Rooij, D.; Anagnostou, E.; Arango, C.; Auzias, G.; Behrmann, M.; Busatto, GF.; Calderoni, S.; Daly, E.; Deruelle, C.; Di Martino, A.; Dinstein, I.; Duran, FLS.; Durston, S.; Ecker, C.; Fair, D.; Fedor, J.; Fitzgerald, J.; Freitag, CM.; Gallagher, L.; Gori, I.; Haar, S.; Hoekstra, L.; Jahanshad, N.; Jalbrzikowski, M.; Janssen, J.; Lerch, J.; Luna, B.; Martinho, MM.; McGrath, J.; Murrator, i F.; Murphy, CM.; Murphy, DGM.; O'Hearn, K.; Oranje, B.; Parellada, M.; Retico, A.; Rossa, P.; Rubia, K.; Shook, D.; Taylor, M.; Thompson, PM.; Tosetti, M.; Wallace, GL.; Zhou, F.; Buitelaar, JK. Cortical and



Subcortical Brain Morphometry Differences Between Patients With Autism Spectrum Disorder and Healthy Individuals Across the Lifespan: Results From the ENIGMA ASD Working Group. *American Journal of Psychiatry*, 175(4):359-369, 2018. (I.F.: 13.391).

Kelly, S.; Jahanshad, N.; Zalesky, A.; Kochunov, P.; Agartz, I.; Alloza, C.; Andreassen, OA.; Arango, C.; Banaj, N.; Bouix, S.; Bousman, CA.; Brouwer, RM.; Bruggemann, J.; Bustillo, J.; Cahn, W.; Calhoun, V.; Cannon, D.; Carr, V.; Catts, S.; Chen, J.; Chen, JX.; Chen, X.; Chiapponi, C.; Cho, KK.; Ciullo, V.; Corvin, AS.; Crespo-Facorro, B.; Croypley, V.; De, Rossi, P.; Diaz-Caneja, CM.; Dickie, EW.; Ehrlich, S.; Fan, FM.; Faskowitz, J.; Fatouros-Bergman, H.; Flyckt, L.; Ford, JM.; Fouche, JP.; Fukunaga, M.; Gill, M.; Glahn, DC.; Gollub, R.; Goudzwaard, ED.; Guo, H.; Gur, RE.; Gur, RC.; Gurholt, TP.; Hashimoto, R.; Hatton, SN.; Henskens, FA.; Hibar, DP.; Hickie, IB.; Hong, LE.; Horacek, J.; Howells, FM.; Hulshoff-Pol, HE.; Hyde, CL.; Isaev, D.; Jablensky, A.; Jansen, PR.; Janssen, J.; Jönsson, EG.; Jung, LA.; Kahn, RS.; Kikinis, Z.; Liu, K.; Klauser, P.; Knöchel, C.; Kubicki, M.; Lagopoulos, J.; Langen, C.; Lawrie, S.; Lenroot, RK.; Lim, KO.; Lopez-Jaramillo, C.; Lyall, A.; Magnotta, V.; Mandl, RCW.; Mathalon, DH.; McCarley, RW.; McCarthy-Jones, S.; McDonald, C.; McEwen, S.; McIntosh, A.; Melicher, T.; Mesholam-Gately, RI.; Michie, PT.; Mowry, B.; Mueller, BA.; Newell, DT.; O'Donnell, P.; Oertel-Knöchel, V.; Oestreich, L.; Paciga, SA.; Pantelis, C.; Pasternak, O.; Pearlson, G.; Pellicano, GR.; Pereira, A.; Pineda, Zapata, J.; Piras, F.; Potkin, SG.; Preda, A.; Rasser, PE.; Roalf, DR.; Roiz, R.; Roos, A.; Rotenberg, D.; Satterthwaite, TD.; Savadjiev, P.; Schall, U.; Scott, RJ.; Seal, ML.; Seidman, LJ.; Shannon, Weickert, C.; Whelan, CD.; Shenton, ME.; Kwon, JS.; Spalletta, G.; Spaniel, F.; Sprooten, E.; Stäblein, M.; Stein, DJ.; Sundram, S.; Tan, Y.; Tan, S.; Tang, S.; Temmingh, HS.; Westlye, LT.; Tønnesen, S.; Tordesillas-Gutierrez, D.; Doan, NT.; Vaidya, J.; van Haren, NEM.; Vargas, CD.; Vecchio, D.; Velakoulis, D.; Voineskos, A.; Voyvodic, JQ.; Wang, Z.; Wan, P.; Wei, D.; Weickert, TW.; Whalley, H.; White, T.; Whitford, TJ.; Wojcik, JD.; Xiang, H.; Xie, Z.; Yamamori, H.; Yang, F.; Yao, N.; Zhang, G.; Zhao, J.; van Erp, TGM.; Turner, J.; Thompson, PM.; Donohoe, G. Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group. *Molecular Psychiatry*, 23(5):1261-1269, 2018. (I.F.: 11.640).

Arango, C.; M. Díaz-Caneja, C.; McGorry, P.; Rapoport, J.; Sommer, I.; Vorstman, J.; McDavid, D.; Marín, O.; Serrano-Drozdzowskyj, E.; Freedman, R.; Carpenter, W. Preventive strategies for mental health. *Lancet Psychiatry*, 5(7):591-604, 2018. (I.F.: 15.233).

Allott, K.; Fraguas, D.; Bartholomeusz, CF.; Díaz-Caneja, CM.; Wannan, C.; Parrish, EM.; Amminger, GP.; Pantelis, C.; Arango, C.; McGorry, PD.; Rapado-Castro, M. Duration of untreated psychosis and neurocognitive functioning in first-episode psychosis: a systematic review and meta-analysis. *Psychological Medicine*, 48(10):1592-1607, 2018. (I.F.: 5.475).

Galderisi, S.; Mucci, A.; Buchanan, RW.; Arango, C. Negative symptoms of schizophrenia: new developments and unanswered research questions. *Lancet Psychiatry*, 5(8):664-677, 2018. (I.F.: 15.233).

Kahn, RS.; Winter van Rossum, I.; Leucht, S.; McGuire, P.; Lewis, SW.; Leboyer, M.; Arango, C.; Dazzan, P.; Drake, R.; Heres, S.; Díaz-Caneja, CM.; Rujescu, D.; Weiser, M.; Galderisi, S.; Glenthøj, B.; Eijkemans, MJC.; Fleischhacker, WW.; Kapur, S.; Sommer, IE; OPTiMiSE study group. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. *Lancet Psychiatry*, 5(10):797-807, 2018. (I.F.: 15.233).

Downs, J.; Dean, H.; Lechler, S.; Sears, N.; Patel, R.; Shetty, H.; Hotopf, M.; Ford, T.; Kyriakopoulos, M.; Diaz-Caneja, CM.; Arango, C.; MacCabe, JH.; Hayes, RD.; Pina-Camacho, L. Negative Symptoms in Early-Onset Psychosis and Their Association with Antipsychotic Treatment Failure. *Schizophrenia Bulletin*, 45(1):69-79, 2019. (I.F.: 6.944).

Fraguas, D.; Díaz-Caneja, CM.; Pina-Camacho, L.; Umbricht, D.; Arango C. Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis. *Schizophrenia Bulletin*, 45(1):57-68, 2019. (I.F.: 6.944).

van der Wee, NJA.; Bilderbeck, AC.; Cabello, M.; Ayuso-Mateos, JL.; Saris, IMJ.; Giltay, EJ.; Penninx, BW.; Arango, C.; Post, A.; Porcelli, S. Working definitions, subjective and objective assessments and experimental paradigms in a study exploring social withdrawal in schizophrenia and Alzheimer's disease. *Neuroscience and Biobehavioral Reviews*, 97:38-46, 2019. (I.F.: 8.037).

Bilderbeck, AC.; Penninx, BWJH.; Arango, C.; van der Wee, N.; Kahn, R.; Winter-van Rossum, I.; Hayen, A.; Kas, MJ.; Post, A.; Dawson, GR. Overview of the clinical implementation of a study exploring social withdrawal in patients with schizophrenia and Alzheimer's disease. *Neuroscience and Biobehavioral Reviews*, 97:87-93, 2019. (I.F.: 8.037).

Kas, MJ.; Penninx, B.; Sommer, B.; Serretti, A.; Arango, C.; Marston H. A quantitative approach to neuropsychiatry: the why and the how. *Neuroscience & Biobehavioral Reviews*, 97:3-9, 2019. (I.F.: 8.037).

Fraguas, D.; Díaz-Caneja, CM.; Ayora, M.; Hernández-Álvarez, F.; Rodríguez-Quiroga, A.; Recio, S.; Leza, JC.; Arango, C. Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis. *Schizophrenia Bulletin*. (In press). (I.F.: 6.944).

Quattrone, D.; Di Forti, M.; Gayer-Anderson, C.; Ferraro, L.; Jongsma, HE.; Tripoli, G.; La Cascia, C.; La Barbera, D.; Tarricone, I.; Berardi, D.; Szöke, A.; Arango, C.; Lasalvia, A.; Tortelli, A.; Llorca, PM.; de Haan, L.; Velthorst, E.; Bobes, J.; Bernardo, M.; Sanjuán, J.; Santos, JL.; Arrojo, M.; Del-Ben, CM.; Menezes, PR.; Selten, JP; EU-GEI WP2 Group.; Jones, PB.; Kirkbride, JB.; Richards, AL.; O'Donovan, MC.; Sham, PC.; Vassos, E.; Rutten, BP.; van Os, J.; Morgan, C.; Lewis, CM.; Murray, RM.; Reininghaus, U. Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. *Psychological Medicine*. (In press). (I.F.: 5.475).

Di Forti, M.; Quattrone, D.; Freeman, TP.; Tripoli, G.; Gayer-Anderson, C.; Quigley, H.; Rodriguez, V.; Jongsma, HE.; Ferraro, L.; La Cascia, C.; La Barbera, D.; Tarricone, I.; Berardi, D.; Szöke, A.; Arango, C.; Tortelli, A.; Velthorst, E.; Bernardo, M.; Del-Ben, CM.; Menezes, PR.; Selten, JP.; Jones, PB.; Kirkbride, JB.; Rutten, BP.; de Haan, L.; Sham, PC.; van Os, J.; Lewis, CM.; Lynskey, M.; Morgan, C.; Murray, RM; EU-GEI WP2 Group. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. *Lancet Psychiatry*. (In press). (I.F.: 15.233).

## RESEARCH SUMMARY

My main area of interest is the neurobiology and neuropsychopharmacology of early-onset psychosis, especially early-onset schizophrenia. We have shown that patients with early-onset psychosis have larger than expected reductions of gray matter and that these reductions are associated with worse outcome and lower antioxidant levels. We have tested experimental treatments for patients with early-onset psychosis based on our findings. To the best of my knowledge, we have the largest cohort of first-episode early-onset psychosis patients followed for more than 15 years now. In addition, as a child psychiatrist, I have always been interested in translational research in early neurodevelopment. I have also published on autism and other neurodevelopmental disorders. I am currently the Principal Investigator for the European Clinical Trials Network for ASD (EU-AIMS-2-TRIALS).

## SIGNIFICANT PUBLICATIONS

Arango, C.; M. Díaz-Caneja, C.; McGorry, P.; Rapoport, J.; Sommer, I.; Vorstman, J.; McDaid, D.; Marín, O.; Serrano-Drozdowskyj, E.; Freedman, R.; Carpenter, W. Preventive strategies for mental health. *Lancet Psychiatry*, 5(7):591-604, 2018. Contribution: I reviewed the evidence for primary and secondary prevention in mental health and led the proposal on how to fill gaps between knowledge, policy, and practice.

Arango, C.; Kapur, S.; Kahn, RS. Going Beyond "trial-and-error" in Psychiatric Treatments: OPTiMiSE-ing the Treatment of First Episode of Schizophrenia. *Schizophrenia Bulletin*, 41(3):546-8, 2015. (I.F.: 6.944). Contribution: I led the dissemination of this EU consortium to optimize treatment in first-episode schizophrenia. As first author, I primarily wrote the paper, summarizing the clinical trials conducted by our consortium and initiatives to achieve our objective.

Arango, C.; Giráldez, M.; Merchán-Naranjo, J.; Baeza, I.; Castro-Fornieles, J.; Alda, JA.; Martínez-Cantarero, C.; Moreno, C.; de Andrés, P; Cuerda, C; de la Serna, E; Correll, C.; Fraguas, D.; Parellada, M. Second-Generation Antipsychotic Use in Children and Adolescents: A Six-Month Prospective Cohort Study in Drug-Naïve Patients. *Journal of the American Academy of Child and Adolescent Psychiatry*, 53(11):1179-1190, 2014. (I.F.: 6.250). Contribution: I was the PI of this large clinical trial (largest ever published in this population with 6 months' follow-up). As first author, I primarily wrote the paper.

Arango, C.; Fraguas, D.; Parellada, M. Differential neurodevelopmental trajectories in patients with early-onset bipolar and schizophrenia disorders. *Schizophrenia Bulletin*, 40(Suppl 2):S138-46, 2014. (I.F.: 6.944). Contribution: As first author, I primarily wrote the paper, summarizing all the studies we have been conducting that differentiate neurodevelopmental pathways in children and adolescents who end up with different psychotic disorders (including schizophrenia and bipolar disorder).

Arango, C.; Rapado Castro, M.; Reig, S.; Castro-Fornieles, J.; González-Pinto, A.; Otero Cuesta, S.; Baeza, I.; Moreno, C.; Graell, M.; Janssen, J.; Parellada, M.; Moreno, D.; Bargalló, N.; Desco, M. Progressive brain changes in children and adolescents with first-episode psychosis. *JAMA Psychiatry* 69(1):16-26, 2012. (I.F.: 16.642). Contribution: As first author, I primarily wrote the paper, summarizing a study for which I was the PI assessing brain changes in the first 2 years after a first psychotic episode in children and adolescents.

Robles, O.; Zabala, A.; Bombín, I.; Parellada, M.; Moreno, D.; Ruiz-Sancho, A.; Arango, C. Cognitive Efficacy of Quetiapine and Olanzapine in Early-Onset First-Episode Psychosis. *Schizophrenia Bulletin*, 37(2):405-15, 2011. (I.F.: 6.944). Contribution: As first author, I primarily wrote the paper, summarizing a clinical trial for which I was the PI assessing the effects of two second generation antipsychotics (SGAs) on cognition in children and adolescents with a first psychotic episode. This was the first RCT ever published comparing two SGAs in a pediatric population.

## **COURSES, QUALIFICATONS, AWARDS AND GRANTS**

- 1998 Selected for the American Psychiatric Association Research Colloquium for Junior Investigators (Neuroimaging). Toronto, Canada.
- 1999 The Theodore and Vada Stanley Foundation Award (2 years). Prediction and prevention of violence in outpatient schizophrenia.
- 2002 Young Scientist Award. 11<sup>th</sup> Biennial Winter Workshop on Schizophrenia. Davos, Switzerland.
- 2004 Young Travel Award. 17<sup>th</sup> ECNP (European College of Neuropsychopharmacology) Congress. Poster: *Safety and tolerability of antipsychotics in children and adolescents: Preliminary results of a longitudinal study*. Stockholm, Sweden.
- 2006 Research Excellence Award for Key Researchers. Spanish Society of Psychiatry Scientific Paper: *Structural Neuroimaging in Adolescents with First Psychotic Episode*. October 2006.
- 2007 Poster Award. European Neuropsychopharmacology. Poster: *Prefrontal cortex N-acetyl-aspartate in early onset psychosis: cognitive correlates, course and predictive value*. 2007.
- 2010 Amadeo Sánchez Blanqué Award.: *Longitudinal 2 year follow up study on insight in a cohort of children and adolescents with a first psychotic episode*. October 2010.
- 2011 CIBERSAM Travel Award. *Cognitive evaluation in adolescents with a first psychotic episode and their first degree families*. October 2011.
- 2013 Best International Paper Award: *Progressive brain changes in children and adolescents with first-episode psychosis*. Research Committee, Álava Hospital, Vitoria, Spain. January 2013.
- 2013 2013 Best National Researcher in Biomedicine Award. Program for Comprehensive Care of Patients with Autism Spectrum Disorders (AMI-TEA). *Diario La Razon*. Madrid, Spain. July 2013.
- 2014 Second Best Psychiatrist of Spain. 1<sup>st</sup> Spanish Healthcare Providers Reputation Study. December 2014.
- 2014 Best Psychiatrist of Spain. *Forbes Magazine* 2014.

## **CLINICAL MANAGEMENT AWARDS**

- 2005 V<sup>th</sup> Community of Madrid Excellence Award (with special honors) to the Adolescent Unit, Psychiatry Department, Hospital General Universitario Gregorio Marañón. Madrid, Spain. February 2005.
- 2006 Pfizer Innovation and Clinical Management Award. Pfizer Chair. Madrid, Spain. September 2006.
- 2006 Assistance Centers and Other Entities 1<sup>st</sup> Award to the Adolescent Unit, Psychiatry Department, Hospital General Universitario Gregorio Marañón. 2006 Patient Service Awards. Farmaindustria Foundation. Madrid, Spain. December 2006.
- 2008 VI<sup>th</sup> Community of Madrid Excellence Award. Winner for quality and excellence in management of all

public facilities within the Community. Adolescent Unit, Psychiatry Department, Hospital General Universitario Gregorio Marañón. Madrid, Spain. December 2008.

- 2009 Clinical Excellence Award from the Spanish Psychiatry Society. Adolescent Unit, Psychiatry Department, Hospital General Universitario Gregorio Marañón. Madrid, Spain. October 2009.
- 2009 "Childhood Awards" from the Autonomous Community of Madrid to the Adolescent Unit, Psychiatry Department, Hospital General Universitario Gregorio Marañón. Madrid, Spain. December 2009.
- 2012 Recognition for Research and Health awarded to the Hospital Gregorio Marañón AMI-TEA team. 2012 Autism Federation of Madrid Awards. Madrid, Spain. March 2012.
- 2012 Best Spanish Center Award for Treatment in Schizophrenia. VII<sup>th</sup> Awards, Best in Class, 2012. Gazeta Médica. Madrid, Spain. October 2012.
- 2012 "Virtual Simulation in Mental Health." 2012 Best Ideas in Health Award. Diario Médico. Barcelona, Spain. November 2012.
- 2013 Quality Excellence Award: Mental Health and Addiction awarded to the Department of Child and Adolescent Psychiatry. Avedis Donabedian Foundation. Madrid, Spain. February 2013.
- 2014 Best Psychiatry Center Award. Best in Class, 2014 Awards. Gazeta Médica and Rey Juan Carlos University. Madrid, Spain. October 2014.
- 2014 Second prize: Adaptation and validation of an instrument for visual assessment of social cognition. Hospital Gregorio Marañón AMI-TEA team. VII<sup>th</sup> Angel Riviere Awards, Spanish Association of Autism (AETAPI). Madrid, Spain. November 2014.
- 2014 Best Psychiatry Service of Spain. I<sup>st</sup> Spanish Healthcare Providers Reputation Study. December 2014.
- 2014 Best Psychiatrist in Spain. Forbes.
- 2015 EFQM 500+ Seal of Excellence. The Club for Excellence in Management and the European Foundation for Quality Management (EFQM). October 2015.
- 2015 Best Psychiatry Service of Spain. II<sup>nd</sup> Spanish Healthcare Providers Reputation Study. December 2015.
- 2015 Leader of the Hospital Excellence Index (HSI). Coordinadas Institute. December 2015.
- 2016 Quality and Innovation in Public Management Awards. Excellence in Public Management Award. Ministry of Finance and Civil Service. June 2016.
- 2016 Best Psychiatry Service of Spain. III<sup>rd</sup> Spanish Healthcare Providers Reputation Study. December 2016.
- 2017 Prize for the Best Psychiatric Service. Best in Class, 2017 Awards. Gazeta Médica and Rey Juan Carlos University. Madrid, Spain. Madrid, October 2017.
- 2017 Best Psychiatry Service of Spain. IV<sup>th</sup> Spanish Healthcare Providers Reputation Study. December 2017.
- 2017 Ibero-American Quality Award for 2017. Ibero-American Foundation for Quality Management FUNDIBEQ. December 2017.
- 2017 Lundbeck Spain Award for excellence in the quality plan: Mental health and addictions. XXIX edition Avedis Donabedian Awards for quality. December 2017.
- 2018 Leader of the Hospital Excellence Index (HSI). Coordinadas Institute. January 2018.
- 2018 Best Psychiatry Service of Spain. V<sup>th</sup> Spanish Healthcare Providers Reputation Study. December 2018.
- 2019 Leader of the Hospital Excellence Index (HSI). Coordinadas Institute. January 2019.

## SCIENTIFIC JOURNALS

### Editorial Board Member:

npj Schizophrenia, Schizophrenia Bulletin, European Psychiatry, European Child and Adolescent Psychiatry, European Neuropsychopharmacology, Spanish Journal of Psychiatry and Mental Health (Co-Editor in Chief), Journal of Child and Adolescent Psychopharmacology, European Archives of Psychiatry and Clinical Neuroscience, Journal of Affective Disorders, International Clinical Psychopharmacology.

### Reviewer:

JAMA, Nature, The Lancet, JAMA-Psychiatry, Molecular Psychiatry, Biological Psychiatry, Psychiatry Research, Schizophrenia Research, and many others.

## OTHERS

- Member of the Executive Committee of the European College of Neuropsychopharmacology (ECNP) since October 2002.
- Member of the International Advisory Board for the Schizophrenia International Research Society.
- Member of the Executive Committee of the Association of Spanish Psychiatry (SEP) November 2002-2005.
- Fellow of the Association of European Psychiatry (AEP) since October 2003.
- President of the Research Commission of Hospital General Universitario Gregorio Marañón since November 2003.
- Member of the Neuroimaging Section of the European Association of Psychiatry since 2003.
- Member of the International Committee of the International Neuropsychiatric Association, 2004.
- Assessor of the European Agency for the Evaluation of Medical Products (EMA). Pre-authorization of medicines for human use.
- Assessor of the Spanish Drug Agency (National Health Department).
- Chair of the ECNP Child and Adolescent Neuropsychopharmacology Network since 2005.
- Member of Educational Committee of the European College of Neuropsychopharmacology (ECNP) since March 2005.
- President of the ECNP Educational Committee since September 2009.
- Secretary of the Spanish Society of Biological Psychiatry, October 2008-October 2012.
- Member of many scientific committees for international meetings.
- Co-chair of the Schizophrenia International Research Society Conference, Florence, Italy, 2010.
- Member of the Schizophrenia International Research Society Board of Directors since 2012.
- Chair of the Schizophrenia International Research Society Publication Committee since 2012.
- Coordinator of the Neuroscience and Mental Health Area of the Gregorio Marañón Research Institute (IISGM) since 2012.
- Board Member of the Gregorio Marañón Research Institute (IISGM) since 2012.
- Member of the Executive Committee of the Gregorio Marañón Research Institute (IISGM) since 2012.
- Member of the Perceived Quality Committee of Hospital General Universitario Gregorio Marañón since 2012.
- Director of the Chair in Child Psychiatry, Alicia Koplowitz Foundation – UCM, 2012-2014.
- Member of the European Brain Council since 2013.
- President-Elect of the European College of Neuropsychopharmacology (ECNP), 2013-2016.
- External referee of the European Research Council Starting Grant, 2013 project proposals.
- International advisor to the European Society for Child and Adolescent Psychiatry since 2014.
- Fellow of the Lundbeck International Neuroscience Foundation since 2014.
- President of the National Commission of the Child and Adolescent Psychiatry Specialty (Ministry of Health, Social Services and Equality) since December 2014.
- Member of the ERA-Net NEURON Strategic Research Group since 2014.
- President of the Executive Committee of Core Curriculum in Psychiatry since 2015.
- President of the European College of Neuropsychopharmacology (ECNP) since 2016.
- Vice Chairman of the Spanish Psychiatry Society since 2016.
- Fluent written and spoken Spanish, English, and Catalan.